Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | STS | P08842 | 2/20 | 0.67 |
| ▸ | TGM2 | P21980 | 9/20 | 0.65 |
| ▸ | F13A1 | P00488 | 6/20 | 0.65 |
| ▸ | TGM1 | P22735 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979984 | 0.88 | GAA (0.74) | POLBSTSTGM2F13A1TGM1 | |
| SCHEMBL5202414 | 0.88 | STS (0.57) | POLBSTSTGM2F13A1TGM1 | |
| SCHEMBL18410584 | 0.88 | TGM2 (0.65) | POLBTGM2F13A1TGM1MEN1 | |
| SCHEMBL3210642 | 0.87 | TGM2 (0.59) | POLBSTSTGM2F13A1TGM1 | |
| SCHEMBL1684972 | 0.86 | TGM2 (0.69) | POLBSTSTGM2F13A1TGM1 | |
| SCHEMBL3910274 | 0.86 | TGM2 (0.64) | POLBSTSTGM2F13A1TGM1 | |
| SCHEMBL4274049 | 0.86 | STS (0.60) | POLBSTSTGM2F13A1TGM1 | |
| SCHEMBL1181084 | 0.86 | PKM (0.73) | TGM2F13A1TGM1L3MBTL1 | |
| SCHEMBL710366 | 0.86 | TGM2 (0.64) | TGM2F13A1TGM1 | |
| SCHEMBL29060791 | 0.86 | TGM2 (0.64) | POLBTGM2F13A1TGM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758884-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| WO-2005113542-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | BACE1, BACE2, APH1B | POLB 3326/4885STS 16/4885TGM2 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.